Table 2.
Whole Blood Analysis after Treatments
| Samples | WBC (103/μL) | HCT (%) | MCV (fL) | RBC (106/μL) | HGB (g/dL) | PLT (103/μL) |
|---|---|---|---|---|---|---|
| PBS | 33 ± 19.3 | 56.4 ± 4.7 | 58.2 ± 0.9 | 9.7 ± 0.8 | 16 ± 0.9 | 916.7 ± 231.4 |
| Empty LCP | 26.5 ± 19.8 | 41.5 ± 6.2 | 47.5 ± 1.5 | 8.72 ± 1.0 | 15 ± 1.7 | 571.7 ± 76.9 |
| Free mRNA | 32 ± 21.0 | 52.4 ± 11.1 | 53.1 ± 5.4 | 9.89 ± 2.0 | 16.3 ± 3.0 | 637.3 ± 54.4 |
| LCP mRNA | 19.8 ± 5.8 | 55.6 ± 3.6 | 55.1 ± 0.9 | 10 ± 0.6 | 16.1 ± 0.9 | 712.3 ± 118.5 |
| Anti-CTLA-4 | 37.5 ± 5.3 | 56.7 ± 3.6 | 57 ± 0.9 | 9.9 ± 0.6 | 16.5 ± 0.9 | 672 ± 38 |
| LCP-mRNA+ anti-CTLA-4 | 5.9 ± 0.8 | 57.1 ± 1.4 | 54.8 ± 1.3 | 10 ± 0.3 | 17.4 ± 0.6 | 883 ± 136.5 |
| Normal range | 2.6–10.1 | 32.8–48.0 | 42.3–55.9 | 6.5–10.1 | 10.1–16.1 | 780–1,540 |